- Clarivate (CLVT, Financial) integrates Pathway Maps into its OFF-X platform for enhanced drug safety assessments.
- Over 30% of drug development failures are due to safety issues; this integration aims to address that problem.
- The new feature facilitates faster, data-driven decisions and reduces costly late-stage failures.
Clarivate Plc (CLVT), a prominent global provider of transformative intelligence, has announced the integration of Pathway Maps into its OFF-X translational safety intelligence solution. This enhancement is designed to streamline safety evaluations in drug development, responding to the significant challenge where over 30% of drug development failures are attributed to safety concerns.
The Pathway Maps feature provides innovative visual tools that merge disease-specific signaling pathways and molecular processes with curated safety data. This integration allows researchers to swiftly identify potential safety liabilities, thus enabling faster and more informed decision-making throughout the drug development process, from early discovery to post-marketing surveillance.
The improved OFF-X platform, combined with Cortellis Drug Discovery Intelligence, offers a comprehensive method for researchers to evaluate both the efficacy and safety of drug development projects. This dual approach helps to reduce costly late-stage failures and accelerates the time to market, thereby optimizing the overall drug development process.
Anne Lecocq, SVP and GM of R&D, Life Sciences & Healthcare at Clarivate, stated, "The ability to assess the safety of drug targets early in development is crucial for reducing late-stage failures and accelerating time to market. At Clarivate, we are committed to providing tools that streamline workflows and offer deeper insights, ultimately improving patient outcomes and creating a healthier future. The introduction of Pathway Maps into OFF-X is a pivotal development in this mission."
Clarivate continues to establish its position as a leader in the field by integrating proprietary physiological and disease pathway visualizations with curated safety data from diverse sources, thereby enhancing risk evaluation and decision-making confidence for researchers.
